Cargando…

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Pediatric Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947636/ https://www.ncbi.nlm.nih.gov/pubmed/29342499 http://dx.doi.org/10.1002/art.40418

Ejemplares similares

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis
por: Campanilho‐Marques, Raquel, et al.
Publicado: (2016)

Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated
por: Almeida, Beverley, et al.
Publicado: (2015)

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

Muscle Biopsy Findings in Combination With Myositis‐Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis
por: Deakin, Claire T., et al.
Publicado: (2016)

Clinically inactive disease in juvenile dermatomyositis – a proposed revision to the printo criteria
por: Almeida, Beverley, et al.
Publicado: (2014)

Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation
por: Wienke, Judith, et al.
Publicado: (2019)

Comparison of the utility and validity of three scoring tools to detect skin disease in patients with juvenile dermatomyositis
por: Campanilho-Marques, Raquel, et al.
Publicado: (2014)

PReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland
por: Moraitis, E, et al.
Publicado: (2013)

Correlation of Low CD73 Expression on Synovial Lymphocytes With Reduced Adenosine Generation and Higher Disease Severity in Juvenile Idiopathic Arthritis
por: Botta Gordon‐Smith, Sophie, et al.
Publicado: (2015)

T Cell Expression of Granulocyte–Macrophage Colony-Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity
por: Piper, Christopher, et al.
Publicado: (2014)

Innate Lymphoid Cells and T Cells Contribute to the Interleukin‐17A Signature Detected in the Synovial Fluid of Patients With Juvenile Idiopathic Arthritis
por: Rosser, Elizabeth C., et al.
Publicado: (2019)

Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
por: Wienke, Judith, et al.
Publicado: (2020)

Long‐Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition
por: Shoop‐Worrall, Stephanie J. W., et al.
Publicado: (2018)

The Association Between Low Socioeconomic Status With High Physical Limitations and Low Illness Self‐Perception in Patients With Juvenile Idiopathic Arthritis: Results From the Childhood Arthritis Prospective Study,
por: Verstappen, Suzanne M. M., et al.
Publicado: (2015)

Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Palmoplantar keratoderma as the preceding cutaneous manifestation of juvenile-onset dermatomyositis
por: Patra, Pratap Kumar, et al.
Publicado: (2022)

Brief Report: The Genetic Profile of Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis
por: Hinks, Anne, et al.
Publicado: (2018)

Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis
por: Duurland, Chantal L., et al.
Publicado: (2014)

The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis
por: Eng, Simon W M, et al.
Publicado: (2014)

A Case of Dermatomyositis Causing Cryptogenic Organizing Pneumonia
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study
por: Tappeiner, Christoph, et al.
Publicado: (2018)

The Vasculopathy of Juvenile Dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2018)

Quantifying Temporomandibular Joint Synovitis in Children With Juvenile Idiopathic Arthritis
por: Resnick, Cory M., et al.
Publicado: (2016)

Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM)
por: McCann, Liza J, et al.
Publicado: (2011)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Brain Structural Changes During Juvenile Fibromyalgia: Relationships With Pain, Fatigue, and Functional Disability
por: Suñol, Maria, et al.
Publicado: (2022)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Identification of Novel Loci Shared by Juvenile Idiopathic Arthritis Subtypes Through Integrative Genetic Analysis
por: Li, Jin, et al.
Publicado: (2022)

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2019)

Whole Blood Gene Expression Profiling Predicts Therapeutic Response at Six Months in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Jiang, Kaiyu, et al.
Publicado: (2014)

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
por: Lerman, Irina, et al.
Publicado: (2019)

Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years
por: Lovell, Daniel J., et al.
Publicado: (2015)

Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database
por: Tappeiner, Christoph, et al.
Publicado: (2015)

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Platelet Glycoprotein Ib α‐Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study
por: Luo, Shan, et al.
Publicado: (2021)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Tubuloreticular inclusions in juvenile dermatomyositis: a diagnostically useful marker?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1jlmhfrgmp8gcmcrol1280qdev